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Abstract
This article reflects that Quality Risk Management (QRM) is operating in a different technological
environment since the ICH Q9: Quality Risk Management [1] guidance was first published in 2005. This
paper explores the array of risk management systems that influence operations in a typical modern
high-tech manufacturing facility. These ‘other’ risk management systems, either directly or indirectly,
inform both the risk assessments and the control strategies developed by QRM. Convergence is
another word for coming together. In order to assure that QRM can fully align and converge within
operations, it must also ensure that it can align with these allied risk management systems.

Introduction
2005 was a very different technological landscape than today. The only available tablet was medicinal.
Wi-Fi in the home was unheard off – no internet, no Netflix. While the I-Pod was newly available, it
was 2007 before the I-phone was launched, and with it the ability to both surf the internet and
photograph our surfing all with one pocket size device. Windows XP was the operating system on our
desktops, and it could only access Facebook if located on a college campus. CDs were used to back up
data. Clouds caused rain showers.

In 2005, the pharmaceutical industry began its journey with Quality Risk Management (QRM)
with the publication of a guidance by the International Council for Harmonisation (ICH). This
body, formed to enhance convergence across global regulatory requirements, published ICH
Q9: Quality Risk Management. [1] The objective was to establish the principles and tools to
enable the application of QRM in a Pharmaceutical Quality System (PQS). The two primary
principles of ICH Q9 are that:
•

The evaluation of the risk to quality should be based on scientific knowledge and
ultimately link to the protection of the patient; and
1
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The level of effort, formality and documentation of the quality risk management
process should be commensurate with the level of risk.

When released, ICH Q9 was an innovative document. It places the patient at the heart of
quality management. It moved the quality conversation from one of absolutes – rights and
wrongs, compliance and non-compliance – to one of balance, where process understanding
is upheld as the key competency of good judgement. The attributes of a product that make it
safe and effective are highlighted as the critical value of the product. Hazards, that could
potentially compromise those attributes, are identified and controlled. At the same time, the
document recognises that zero risk is not always attainable, but that it should be as low as
reasonably possible. [2]
QRM was designed to sit within the PQS and influence and inform quality controls across the product
lifecycle. It was not intended as a stand-alone guidance and was shortly supported by the publication
in 2008 of ICH Q8: Pharmaceutical Development [3] and ICH Q10: Pharmaceutical Quality System [4].
The essence of the trilogy is that the critical-to-quality attributes (CQA’s) of a product should be
identified early in the development lifecycle and that, with the correct application of the PQS, those
attributes should be preserved and protected throughout the remainder of the product lifecycle. In
business terms this is referred to as the preservation of value [5]. Any actions taken in response to
issues, or any changes made to a process, should have the intent of preserving value, improving
control, and reducing risk to product.
As a result of the trilogy, the future of pharmaceutical manufacturing was altered to one of process
understanding, control, and improvement. Quality management and process management were
intertwined. Management Review, and the role of management in general, became critical to ensuring
that the real-world outcomes of control were monitored and fed back to the source of control.
Prevention of issues became as important, if not more important, than reacting to them. ICH Q9 was
a key influencer of these paradigm changes.
However, 15 years on, the guidance is somewhat dated. The modern PQS is much less site-specific
than even a decade ago, residing as it typically does within a global organisation, with advancing
technology across a diversified lifecycle. Outsourcing and extended supply chains have become
common. In many business sectors, primarily in response to the global recession of 2008, Risk
Management has found a more central role in enterprise management and as a result, it too, has
evolved. With increasing diversity and complexity, QRM must continue to align and remain central to
management objectives.
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Figure 1: Risk Management Lifecycle from ICG q9

The Current Landscape
In 2017, Yu & Kopcha of the FDA [6], summarised the future of pharmaceutical quality when
they stated that the fundamental destination was ‘a maximally efficient, agile, flexible,
pharmaceutical manufacturing sector that reliably produces high quality drugs without
extensive regulatory oversight’.
While this sounds like an ambitious objective, Yu & Kopcha recognised and detailed the
substantial progress that had already been made towards this goal including, Process
Analytical Technology (PAT) in 2004, Current Good Manufacturing Practices (cGMP) for the
21st Century (2004), Quality by Design (QbD) (2009), and Emerging Technology (2017) [3] [7]
[8] [9]. The authors concluded that regulatory guidance has delivered on support for
innovation and modernisation. Regulatory focus has indeed encouraged a progression from
off-line lagging finished product testing to real time process monitoring. This approach has
the added benefit of developing process understanding and resolving uncertainties with
product and process. This focus supports the pathway to agility and flexibility, as mentioned
by Yu & Kopcha.
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In Appendix 1, ICH Q10 notes that regulatory relief may be available to organisations that
could establish the effectivity of the PQS, in terms of process understanding and control. ICH
Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle
Management [10] offers further regulatory flexibility for organisations with the appropriately
scientific risk-based approaches. The ability to demonstrate that innovation, improvement,
and change are driven by science based informed decision making is critical. When ICH Q9
was published its focus was to establish a systematic approach to quality risk management. It
proposed a traditional risk management approach, with the emphasis is on identifying and
mitigating risk. ICH Q10 later broadened the scope and included an ambition to support
innovation and continuous improvement
However, progress in terms of the application of real time measures, and perhaps innovative
and disruptive technology in general, is slow. An oft quoted headline article in the September
3rd 2003 edition of the Wall Street Journal [11] noted that ‘‘the pharmaceutical industry has
a little secret: even as it invents futuristic new drugs, its manufacturing techniques lag far
behind those of potato-chip and laundry soap makers’! In 2018, industry publications were
still referring to the 2004 FDA PAT guide as an ‘aspirational guidance’ [12]. Despite the
regulatory interventions, modernisation and progress continue to be challenging for
established manufacturing operations.
Product and processes technologies are evolving at a wonderous rate. The application of
complex systems to simplify processes is paradoxically making systems more difficult to
understand. Complex systems are littered with interdependencies that are hard to determine.
Organisational literature considers complexity as an important factor in influencing
organisations, particularly in the migration from the industrial age (2.0) to the knowledge era
(4.0) [13].
The industry must increasingly rely on its innovation partners, the developers of the software,
automation, robotic, data analysis, and the detection and measurement systems that it integrates into
its complexity. It must also rely on the risk management systems used to design, develop, and manage
these complimentary products and services. The industry has been cautious in its approach to this
opportunity.
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What are these ‘other’ risk management systems?
Progress, improvement and innovation in the industry are essential for future
competitiveness. However, they also necessitate the integration of technology, information
systems, data analysis, automation, and intelligent systems. In this authors opinion, the need
for alignment between the approach adopted by QRM in the pharmaceutical sector and the
risk management systems of supporting sectors is pivotal to progress.

Process Control Systems
The close connection between product quality and process control is accelerating with the
journey to Pharma 4.0. The term Pharma 4.0 is a play on the 2011 German government
initiative – Industry 4.0 – which created the concept of the cognitive factory, where systems
and equipment communicate and self-optimise [14]. Converging the ability to access, analyse
and understand large volumes of multi-variate data to create process understanding with an
increased use of automation, robotics and machine intelligence, the move to real time
product quality control and release has never been closer or more inviting. The emergence of
virtual technology to create simulated processes – known as digital twins- allows process
changes, troubleshooting, or improvements to be conceptualised and modelled off-line
before implementation in real environments.
All these systems, and the software, robotics, and automation required to support the
technologies, are developed in different industry sectors, each of which will have applied a
risk management approach to their design and testing. For the industries, including pharma,
using these technologies, these processes need to be understood and potentially verified.
Life science specialists are unlikely to have the required skills to evaluate the risk-based
approach to software development, automation controls, complex algorithms, and
modelling. Even with specialist knowledge, this is a challenge within those industries [15] and
the subject of intense and continued research. Large scale software systems are typically
complex and are often themselves, the output of several converging development processes.
While there is no requirement to duplicate these risk management processes – they do need
to be verified as appropriate. This confidence is enhanced if the risk management processes
used are based on recognised standards and are structured similarly to those of the user.
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The software development industry applies and relies on risk management processes
throughout the development lifecycle. Many of the standards used in this sector are
published by the IEEE (Institute of Electrical and Electronics Engineers) and the ISO
(International Standards Organisation). The most common is ISO IEC IEEE 12207:2017
Systems and software engineering — Software life cycle processes [16], a software
engineering standard that defines the software engineering process, activity, and tasks
associated with a software life cycle from conception through to retirement. There are similar
supporting standards for hardware design, security systems, etc.
ISO IEC IEEE 16085:2006 Systems and software engineering - Life Cycle Processes-Risk
management [17]is currently undergoing an update to align with the enterprise risk
management framework described in ISO 31000:2018 Risk Management Guidelines [18] The latter
being a risk management guide for ‘top management’ providing a framework for the various risk
management systems within an organisation e.g. safety, environment, IT, finance and, hopefully,
quality.

Increasingly and at a rapid rate, QRM must accept the need to recognise, rely upon, align, and
accept the application of international standards of practice and accredited systems within
these specialities. QRM assessments will both rely on the risk controls applied to these
systems and build on the risk control strategies developed. Therefore, it is critical to ensure
that the language, methods, terminology and framework of the QRM process continues to
enable alignment with these standards.
Project Management
While processes and the associated critical control specifications are developed by process
designers, the translation to equipment and technical specifications and the resulting
procurement decisions are often made by specialist project engineers. In modern large-scale
projects, many of the key decisions in relation to process design, and the supporting
measurement and monitoring technologies, are made in the project management
environment.
Facility design has evolved into a separate expertise, aimed at maximising space and the
effectiveness of the process. These engineers will conserve the process value criteria, while
seeking to integrate the efficient flow of materials, people and information, and the required
work environment, into a single well-functioning system. Furthermore, it is not unusual for
6
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the construction of a facility to be in progress before the details of the process controls are
fully understood, adding a further uncertainty to the process.

Table 1: Various Definitions of the word 'Risk' likely to be encountered on an Engineering Program
(Stein/Maynard) [19]

While process and product risk management criteria are key, these engineers must balance
these requirements with other risk considerations including safety, environment, schedule,
7
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cost, resources, security, capacity, yield, adaptability, reliability, supply chain, ease of
maintenance and repair, business continuity etc.
Constraints impacting risk are also inevitable e.g., footprint, planning permissions, costs,
resources and schedules. Various solutions will be designed, modelled and revised in the
process. In order to design a safe and reliable facility layout, a complete understanding of the
contribution to risk from all these drivers must be assessed and understood. [20] [21]. Tradeoffs are inevitable and must be informed by a comprehensive, integrated and aligned risk
management system. Changes are also expected, and these must be assessed with impact to
all the above-mentioned risks. Divergence in risk vocabulary, classification, or assessment
methods increases the likelihood that errors or misjudgements will be made.
With over 700,000 members, the Project Management Institute (PMI) is the world's largest
not-for-profit membership association for the project management profession. In 2011, the
organisation aligned with INCOSE (International Council on Systems Engineering) to address
concerns in relation to risk vocabulary. This is exemplified by the various definitions of risk
identified. (Table 1) [19]. The confusion extended beyond these definitions and beyond the
two sectors identified. The divergence was further complicated by different risk management
systems and language within the customer industry sectors (e.g., pharmaceutical, medical
device, construction, automobile, etc.) and in the supporting processes (safety, human
factors, IT, legal, disaster management, etc) - each having developed their risk management
practices, terminology, and publications separately and independently.
To address these anomalies, the PMI-INCOSE Risk Management Collaboration committed to
pioneering a systems approach to engineering program risk management using the ISO 31000:2018
Risk Management Principles and Objectives [18] model as a guide to enabling a consolidated
approach. Once again, the ISO 31000 standard provided a useful umbrella for alignment. The exercise,
did, however highlight the confusion that arises when different frameworks and language is applied.
The objective of the collaboration was to address the problems related to inconsistencies in risk
management-related terminology and practices, and to facilitate effective integration of risk
management into organizations. The process highlighted the risks associated with inconsistent
terminology. The output of this process (which is ongoing) contributed to the 2017 publication of the
6th Edition of the PMBoK® Guide - A Guide to the Project Management Body of Knowledge [22], a
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widely accepted standard in project management and the fundamental text for Project Management
Professional certification by the PMI.

ASTM
In 2003, the ASTM (formally known as the American Society for Testing and Materials)
established Committee E55. The main objective of this committee was to support the
application of Process Analytical Technology (PAT) in the pharmceutical sector with technical
guides and standards. The initial structure of E55 included three main subcommittees: E55.01
- PAT System Management; E55.02 - PAT System Implementation and Practice; and E55.91 Terminology. The committee expanded its scope in 2006 from the implementation of PAT to
the much broader Pharmaceutical Manufacturing, again with a focus on the ‘development of
standardised nomenclature and definitions of terms, recommended practices, guides, test
methods, specifications, and performance standards for the manufacture of pharmaceutical
products’.
In 2009, the E55 committee published ASTM E2476 Standard Guide for Risk Assessment and
Risk Control as it Impacts the Design, Development, and Operation of PAT Processes for
Pharmaceutical Manufacture [23]. This standard, since updated in 2016, provides guidance
on the assessment of risks in the PAT development process. While focused on one aspect of
the process, the application of PAT, the standard is aligned with ICH Q9. This alignment is
helpful, as it ensures that the overall application is consistent.

Reliability
Reliability engineering focuses on the equipment, instruments and control systems that are
relied upon to protect the product value (CQA’s) through process control. These controls are
studied to prevent them failing. Potential degradation factors are identified and appropriate
preventative actions, such as test plans, calibration schedules, maintenance plans, spare
parts, etc are actioned. The goal is to maintain reliability for the lifetime of the control,
therefore aging/ reduced performance is a key concern.
Like risk management and, indeed, it does achieve the same objective, it is focused on causal
factors and detecting and preventing failure before it impacts the process. It is ‘ahead’ of the
9
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process failure. Its focus is on preventing the risk control system from failing – rather than the
process itself. Reliability belongs to a family of risk management techniques that focus on the
Layers of Protection [24] around a control point. Since ICH Q8/9/10, process control is placed
more centrally to the preservation of product quality. It is increasingly reliant on a range of
experts in the supporting disciplines of engineering, automation, and instrumentation.
Increasing in popularity in pharmaceutical manufacturing operations, reliability engineering
is designed to address complex systems. It involves the use of many of the common risk
management techniques, but also considers design reliability analysis, human factors,
predictive maintenance, fault tolerances, operational and maintenance induced failures,
failure reporting (FRACAS), measurement and monitoring, chaos and stress studies, etc. It has
developed as a discipline within the engineering profession, recognised by both the IEE
(Institute of Electrical and Electronics Engineers) and the ASQ (American Society for Quality).
The discipline is also supported by a newly published (2014) family of ISO standards – ISO
55000 [25]. Based on a previously used PAS 55 (Publicly Available Specification), which was
widely applied within the energy and transport sectors, the ISO 55000 suite of standards is
aimed at assuring that the assets within an organisation support process control, while
balancing with safety, capacity, schedules, and costs. Risk management and informed
decision making are central to the approach described. These standards are designed to align
with both the quality system standards, as described in the ISO 9000 suite of standards, and
with ISO 31000.

Combination Products
Innovations in technology do not just apply to processes. Products themselves are evolving
and will continue to evolve. The combination product market (drugs and devices) is predicted
to grow to a USD 177.7 billion industry by 2024 [26]. Among the products expected to show
strong growth are transdermal patches and inhalers.
The devices in these products are designed and developed using a separate risk management
framework – ISO 14971:2019 Application of Risk Management to Medical Devices [27] . The
first edition of this standard was published in 2000, with two further updates culminating in
the latest edition in 2019. Published by the ISO, this standard focuses on product risk through
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the entire lifecycle, including manufacturing. During the most recent update of ISO 14971,
compatibility with the framework described in ISO 31000:2018 Risk Management Guidelines,
and with the general definitions therein, was discussed. The advantage to this alignment is
that it would allow ISO 14971 to sit within an enterprise risk management framework based
on the same vocabulary.
This risk management framework is supported by a glossary of supporting terminology ISO/IEC GUIDE 63:2019 Guide to the development and inclusion of aspects of safety in
International Standards for medical devices [26]. Unfortunately, this is not the only glossary
of Risk Management Terminology in the ISO lexicon. Currently the pharmaceutical industry
draws on the ISO/IEC Guide 51:2014 Safety Aspects – Guidelines for their Inclusion in
Standards [25]. While very similar, it is important that these guides remain aligned.
To further demonstrate the continued inter-weave of risk management systems, many
medical devices now contain software, which is often required to communicate with other
systems such as hospital monitoring systems. This software is typically developed using yet
another ISO risk management guide - ISO/IEC 80001 – Application of Risk Management For
IT-Networks Incorporating Medical Devices [28], written for the management of the safety
and security of medical devices connected to IT networks.
For combination products i.e., drug/device combinations, the appropriate risk-based
approach is applied to each component during development, with a combined and somewhat
duplicating system applied to the resulting combination. This divergent approach can become
challenging when simple devices are combined with hazardous medicine e.g. fentanyl patches. In
this example, the risk assessment of the device alone may not be comparable to risk to the patient of
the combined therapy. Alternatively, low risk medication such as insulin, epinephrine, or asthma
medication are, because of the acuteness of the clinical need, heavily dependent on the correct
deployment of the device – making the function of the device critical. Independently assessing each
element with separate risk management systems may not offer the full control strategy for the
treatment. Additionally, in practice, one sector typically adopts an established product from the other
and the novelty is in the combination.

When adopting a product partner, the specialists within one sector evaluate the risk-based
approach of the other, an approach with which they may be less familiar. While there is much
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common ground between the two risk management systems – any divergence must increase
the risk of misinterpretation and error.
Agencies, e.g. FDA, that oversee both pharma and the device sectors are familiar with the risk
management approach in each sector i.e. pharma or medical device. However, individual
product assessors, within CDER (Centre for Drug Evaluation and Research) or CDRH (Centre
for Device & Radiological Health), are typically more familiar with the risk approach adopted
within their own sector. When a combination product is submitted for review, it is assessed
by either CDER or CDRH, based on the dominant therapeutic effect.
As an added complexity, many emerging therapies in the area of tissue, cell, or gene therapies
require medical devices to administer the product at the point of care. Some of these devices,
such as cell sorters, have been assigned to CBER for review, as the main therapeutic effect is
the biological entity. While there is no evidence that the use of separate risk management
systems adds to the time or complexity of the evaluation of such products –alignment could
not hinder these assessments. Alignment with emerging risk management principles within
transfusion medicine, with its added consideration of donor and clinical risk management
cannot be ignored either.
Finally, the risk assessment and management of the processes used to manufacture
combination products is an intertwine of both the pharma (ICH Q9) and the medical device
(ISO 14971) standards – sometimes within an enterprise aligned with ISO 31000. While the
Risk Management File required by the ISO 14971 system can accommodate the requirements
of ICH Q9, the reverse application imposes additional requirements. To facilitate the further
convergence of combination products, including tissue/device combinations, continued
alignment of risk management frameworks and terminology is important.

Future ‘Combinations’
Every 5 years or so, the ‘Big Four’ accountancy firms each publish their projection for the
future of industry sectors, including the pharmaceutical and life sciences sector [29] [30] [31]
[32]. These publications give an insight into the challenges ahead for the industry and the
emerging technology trends. Among the predicted ‘seismic and disturbing’ shifts to 2030 is
the emergence of new therapies based on new technologies such as gene therapies, cell
12
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therapies, 3D printing, nanotechnologies, and predictive analytics. Nano technologies, tissue
engineering, and robotics are envisaged as essential specialty partners to deliver these future
therapies. The latter two forces being highly reliant on data powered insights and modelling.
Ernst and Young [35] highlighted that both pharma and biopharma needed to develop their
own core competencies into the future while developing the pathways to integrate
innovations from other technology sectors. Assessing the risks involved when combining
technologies from external sectors with internal systems must be seamless. In order to avoid
creating barriers to progress, the pharmceutical industry must consider frameworks to
facilitate such convergences, while preserving the need to apply a bespoke and tailored risk
management system that supports the unique concerns of the pharmaceutical,
biopharmaceutical, ATMP (Advanced Therapeutic Medicinal Products), and C/GT (Cell & Gene
Therapies) sectors.
Conclusion
There are many drivers of innovation and technical and operational complexity in modern
pharmaceutical operations and with them many risks to be managed. The manufacture of good
quality medicinal product is the core competency of pharmaceutical organisations and QRM, which is
designed to enhance the control of the manufacturing process. However, it must align with the wider
organisational complexity and integrate with other risk management strategies to achieve its intended
goals.
Risk Management Systems, like other processes, are not truly effective when analysed in isolation. A
process that has been assessed for one objective e.g. process safety does not necessarily meet the
requirements of another objective e.g. quality. The appropriate control of a safety risk may occur at
the expense of the optimum control of a product quality risk. These risks must be balanced and
manged in a harmonised and holistic manner.

Traditional risk management, with its focus on assessing singular granular parts – one factor
at a time – can fail to capture the impact of all the parts moving together. It establishes
mitigations for risks as isolated events. The simplification of one complexity (e.g. real time
process measurement) may be applied at the expense of increasing another (e.g. human
process understanding). The economist Nassim Table [33], noted that a city is not a big
village, and that a corporation is not a large small business. Similarly, an automated process
is not a manual process with computers attached. It has added layers of complexity, that
process understanding alone cannot re-construct. Separating the analysis of the process from
13
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the associated information management systems does not construct the overall risk picture.
The integration of these risk management complexities into an overall risk management
dynamic is essential and exceptionally challenging [34] This is the responsibility of the
manufacturing organisations and cannot be prescribed by the regulatory authorities.
Those ‘other’ risk management strategies may be internal (e.g., safety, IT, finance) or external
(e.g., project management, software development, automation). QRM must both rely on the
output of these risk-based approaches and must integrate the controls required into the
overall control strategy. The industry cannot seek to rework these assessments, as it has
neither the competency nor the resources to do so. But it must be assured that it can rely on
the output of these assessments and it must align them within its own operation.
Convergence with other sectors is facilitated by using common terms, vocabulary, methods
and approach. Aligned risk management systems facilitate the safe management of the
complexity of convergent technologies.
It is therefore important that QRM is fully integrated and aligned with an organisation’s
enterprise risk management system, QRM can identify and preserve product quality at the
top management level from the critical and complex decision-making that will most challenge
it. QRM places product quality within the hierarchy of values within the organisation. The
Enterprise Risk Management system will manage and balance these criteria throughout the
lifecycle, ideally protecting them from cost reductions, schedule pressures, resource
constraints, etc –all pressures that are primarily controlled outside the PQS. The PQS will
manage some aspects of risk control, through procedural controls, change management, or
CAPA. Control of risk from other sources e.g., data management, asset management,
software, hardware and systems management, security, facility management will be
managed by other, and hopefully complimentary, risk management systems.
That processes within the same business enterprise can align to achieve common objectives
is important. The alignment of these objectives and the management of the associated risks
is the role of the top management team. This is facilitated when all supporting risk
management systems have a common framework and use common terminology.
Consequentially, the pharmceutical industry should consider the wider adoption of ISO
31000. This is not an industry specific standard. It is a management standard designed to
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support the interweave of risk management standards at an enterprise level. It sits within the
boardroom of organisations, where most key decisions are made
Manville & Ober [45] stated that ‘We're in a knowledge economy, but our managerial and
governance systems are stuck in the Industrial Era.’ Information, data and knowledge is
fundamental to risk management. The rate of change of information technology and its
applications is unprecedented. For QRM to be effective, PQS owners should also recognise
the need to ensure that the environment in which it operates has an appropriate macro risk
management structure. Recognition and alignment with ISO 31000 would provide this cover.
While it not required that ICH Q9 formally align with the ISO standard, applicants should
recognise its growing application and influence.
Keeping a tool, such as a risk management standard, aligned with technology and modern
business approaches is challenging, but critical. It is critical that ICH Q9 remains influential
and avoids a divergence in language, approach, or method. Currently the ICH Q9 document is
consistent with ISO 31000. It may be wise to preserve this connection.
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